FANCL
Basic information
Region (hg38): 2:58159243-58241410
Previous symbols: [ "PHF9" ]
Links
Phenotypes
GenCC
Source:
- Fanconi anemia complementation group L (Strong), mode of inheritance: AR
- Fanconi anemia complementation group L (Strong), mode of inheritance: AR
- Fanconi anemia (Supportive), mode of inheritance: AR
- Fanconi anemia complementation group L (Strong), mode of inheritance: AR
- Fanconi anemia complementation group L (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Fanconi anemia, complementation group L | AR | Allergy/Immunology/Infectious; Cardiovascular; Hematologic; Oncologic | Specific treatments can help manifestations (eg, oral androgens for blood counts; G-CSF for neutrophil count); HSCT can be curative, but solid tumor risk may remain; Surveillance for complications such as bone marrow failure is recommended; Fanconi anemia can involve congenital cardiac (and other) anomalies, and awareness may allow early management | Audiologic/Otolaryngologic; Allergy/Immunology/Infectious; Cardiovascular; Dermatologic; Gastrointestinal; Hematologic; Musculoskeletal; Neurologic; Oncologic; Ophthalmologic; Renal | 12973351; 20301575; 22720145; 25754594 |
ClinVar
This is a list of variants' phenotypes submitted to
- Fanconi anemia (37 variants)
- Fanconi anemia complementation group L (3 variants)
- not provided (2 variants)
- VATER association (1 variants)
- Fanconi anemia complementation group A (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FANCL gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 109 | 115 | ||||
missense | 209 | 216 | ||||
nonsense | 15 | 16 | 31 | |||
start loss | 5 | |||||
frameshift | 20 | 21 | 44 | |||
inframe indel | 4 | |||||
splice donor/acceptor (+/-2bp) | 20 | 20 | ||||
splice region | 1 | 17 | 38 | 2 | 58 | |
non coding | 26 | 134 | 34 | 194 | ||
Total | 38 | 59 | 245 | 249 | 38 |
Highest pathogenic variant AF is 0.00000658
Variants in FANCL
This is a list of pathogenic ClinVar variants found in the FANCL region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-58159250-T-G | Fanconi anemia complementation group L | Uncertain significance (Jan 13, 2018) | ||
2-58159314-TAACA-T | Fanconi anemia | Uncertain significance (Jun 14, 2016) | ||
2-58159331-T-C | Fanconi anemia complementation group L | Uncertain significance (Apr 27, 2017) | ||
2-58159380-A-T | not specified | Uncertain significance (Sep 22, 2023) | ||
2-58159419-A-C | not specified | Uncertain significance (Jun 10, 2022) | ||
2-58159432-T-C | Fanconi anemia complementation group L | Likely benign (Jan 12, 2018) | ||
2-58159445-A-G | not specified | Uncertain significance (Jul 19, 2022) | ||
2-58159458-A-C | not specified | Uncertain significance (Apr 17, 2023) | ||
2-58159469-G-A | Fanconi anemia complementation group L • not specified | Uncertain significance (Jan 26, 2023) | ||
2-58159478-A-G | not specified | Uncertain significance (May 08, 2024) | ||
2-58159484-G-C | Fanconi anemia complementation group L | Uncertain significance (Jan 13, 2018) | ||
2-58159487-A-G | not specified | Uncertain significance (Mar 15, 2024) | ||
2-58159493-A-C | not specified | Uncertain significance (Apr 12, 2024) | ||
2-58159584-C-T | not specified | Uncertain significance (Apr 06, 2024) | ||
2-58159600-T-C | Fanconi anemia complementation group L | Uncertain significance (Jan 12, 2018) | ||
2-58159600-T-G | Fanconi anemia complementation group L | Uncertain significance (Jan 15, 2018) | ||
2-58159608-A-C | not specified | Uncertain significance (Jun 20, 2024) | ||
2-58159637-C-T | Fanconi anemia complementation group L | Uncertain significance (Jan 13, 2018) | ||
2-58159659-T-TGATG | not specified | Uncertain significance (Mar 14, 2023) | ||
2-58159670-T-C | Fanconi anemia complementation group L | Benign/Likely benign (Jun 10, 2019) | ||
2-58159676-G-A | Fanconi anemia complementation group L | Uncertain significance (Jan 13, 2018) | ||
2-58159681-A-T | not specified | Uncertain significance (Sep 22, 2022) | ||
2-58159769-T-G | Fanconi anemia | Likely benign (Nov 24, 2023) | ||
2-58159770-G-C | Fanconi anemia | Uncertain significance (May 04, 2022) | ||
2-58159772-T-C | Fanconi anemia | Uncertain significance (Oct 07, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
FANCL | protein_coding | protein_coding | ENST00000402135 | 14 | 82130 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
5.94e-23 | 0.000106 | 125654 | 0 | 94 | 125748 | 0.000374 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.31 | 251 | 199 | 1.26 | 0.00000943 | 2494 |
Missense in Polyphen | 40 | 46.181 | 0.86616 | 582 | ||
Synonymous | -0.598 | 73 | 66.8 | 1.09 | 0.00000323 | 684 |
Loss of Function | -0.934 | 31 | 25.9 | 1.20 | 0.00000117 | 318 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00119 | 0.00119 |
Ashkenazi Jewish | 0.000496 | 0.000496 |
East Asian | 0.000164 | 0.000163 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000344 | 0.000343 |
Middle Eastern | 0.000164 | 0.000163 |
South Asian | 0.000425 | 0.000425 |
Other | 0.000327 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Ubiquitin ligase protein that mediates monoubiquitination of FANCD2 in the presence of UBE2T, a key step in the DNA damage pathway (PubMed:12973351, PubMed:16916645, PubMed:17938197, PubMed:19111657, PubMed:24389026). Also mediates monoubiquitination of FANCI (PubMed:19589784). May stimulate the ubiquitin release from UBE2W. May be required for proper primordial germ cell proliferation in the embryonic stage, whereas it is probably not needed for spermatogonial proliferation after birth. {ECO:0000269|PubMed:12973351, ECO:0000269|PubMed:16916645, ECO:0000269|PubMed:17938197, ECO:0000269|PubMed:19111657, ECO:0000269|PubMed:19589784, ECO:0000269|PubMed:24389026}.;
- Disease
- DISEASE: Fanconi anemia complementation group L (FANCL) [MIM:614083]: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. {ECO:0000269|PubMed:12973351}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Fanconi anemia pathway - Homo sapiens (human);Ubiquitin mediated proteolysis - Homo sapiens (human);Fanconi Anemia Pathway;DNA Repair;Fanconi anemia pathway;BARD1 signaling events
(Consensus)
Recessive Scores
- pRec
- 0.284
Intolerance Scores
- loftool
- 0.985
- rvis_EVS
- -0.29
- rvis_percentile_EVS
- 33.2
Haploinsufficiency Scores
- pHI
- 0.324
- hipred
- N
- hipred_score
- 0.449
- ghis
- 0.625
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.875
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Fancl
- Phenotype
- endocrine/exocrine gland phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; embryo phenotype; pigmentation phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; vision/eye phenotype; skeleton phenotype;
Gene ontology
- Biological process
- DNA repair;protein monoubiquitination;cellular response to DNA damage stimulus;gamete generation;interstrand cross-link repair;regulation of cell population proliferation
- Cellular component
- nuclear envelope;nucleoplasm;cytoplasm;nuclear body;intracellular membrane-bounded organelle;Fanconi anaemia nuclear complex
- Molecular function
- ubiquitin-protein transferase activity;protein binding;ubiquitin protein ligase binding;metal ion binding;ubiquitin protein ligase activity